Management of Ampicillin‑Resistant Escherichia coli Infections

Resistance Mechanisms that Limit Augmentin Efficacy

Extended‑spectrum β‑lactamase (ESBL) production renders E. coli resistant to amoxicillin‑clavulanate. The presence of ESBLs is a key determinant of treatment failure with Augmentin. [1][2]
AmpC β‑lactamase hyperexpression can also confer resistance to amoxicillin‑clavulanate. Although AmpC is usually not inducible in E. coli, occasional hyperexpression defeats clavulanic acid inhibition. [1][2]
Intrinsic mechanisms such as porin loss or efflux‑pump overactivity are not overcome by clavulanic acid and lead to Augmentin resistance. These non‑β‑lactamase pathways bypass the inhibitor’s activity. 1

Carbapenems remain the most reliable agents for infections caused by ESBL‑producing E. coli. ESBL strains retain susceptibility to carbapenems, making them the preferred choice for serious or high‑risk infections. [1][2]

Amoxicillin alone should not be used empirically for E. coli infections. Global surveillance shows a median resistance rate of approximately 75 % to amoxicillin among E. coli isolates. 3
Amoxicillin‑clavulanate is recommended as a first‑choice empiric agent for uncomplicated lower urinary tract infections (UTIs). It achieves higher susceptibility rates than amoxicillin alone in this setting. 3
When ESBL risk factors are present (e.g., recent hospitalization, healthcare exposure, prior broad‑spectrum antibiotic use), avoid amoxicillin‑clavulanate and select a carbapenem. This strategy mitigates the high likelihood of resistance. [1][2]
Alternative first‑line agents for uncomplicated UTI include nitrofurantoin or fosfomycin, which may provide more predictable activity than amoxicillin‑clavulanate. These agents are especially useful when local resistance patterns are uncertain. [4][3]